Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-09-26, Stock:LLY, The news for the past five days is as follows:
2018-09-19: NEWS1: Lilly's Elanco animal health unit's IPO priced at $24/share.NEWS2: Elanco Animal Health prices IPO above expected range.NEWS3: Elanco Announces Pricing of Initial Public Offering.NEWS4: J&J Files NDA for Erdafitinib in Urothelial Cancer Indication.NEWS5: J&J Files NDA for Erdafitinib in Urothelial Cancer Indication.NEWS6: Lilly's Elanco Rises After $1.5 Billion Animal-Health IPO.NEWS7: Lilly's Elanco Raises $1.5 Billion in Animal-Health IPO.NEWS8: J&J Files NDA for Erdafitinib in Urothelial Cancer Indication.NEWS9: Pharma Stocks: Pfizer’s Revenue Trend and 2018 Estimates.NEWS10: Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff.NEWS11: Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff.NEWS12: Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff.NEWS13: Pharma Stocks in Review: A Valuation Comparison.
2018-09-20: NEWS1: Animal health firm Elanco surges 41 percent on debut.NEWS2: Eli Lilly Prices Animal Health Unit IPO at $24 Per Share.NEWS3: Eli Lilly Prices Animal Health Unit IPO at $24 Per Share.NEWS4: Elanco Animal Health stock soars more than 35% in trading debut.NEWS5: Eli Lilly Prices Animal Health Unit IPO at $24 Per Share.NEWS6: Elanco CEO on IPO, animal health focus.NEWS7: Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates.NEWS8: Pharma Stocks: Allergan’s Revenue Trend and 2018 Estimates.NEWS9: Elanco’s $1.7 billion IPO looks too pricey, and here’s why.NEWS10: Elanco’s $1.6 billion IPO looks too pricey, and here’s why.NEWS11: D-Day Nearing For Antares Pharma.NEWS12: D-Day Nearing For Antares Pharma.
2018-09-21: NEWS1: Health Care Sector Update for 09/21/2018: CRSP,BGNE,XOMA,LLY,AGEN,INCY,MRK.NEWS2: Health Care Sector Update for 09/21/2018: CRSP,BGNE,XOMA,LLY,AGEN,INCY,MRK.NEWS3: [$$] Lilly Approval to Spur Migraine-Prevention Market in Europe.NEWS4: Market Rallies Despite Trade Worries: 5 Blue-Chip Picks.NEWS5: Market Rallies Despite Trade Worries: 5 Blue-Chip Picks.NEWS6: Market Rallies Despite Trade Worries: 5 Blue-Chip Picks.NEWS7: Health Care Sector Update for 09/21/2018: AGEN, XOMA, LLY, BGNE.NEWS8: Health Care Sector Update for 09/21/2018: AGEN, XOMA, LLY, BGNE.NEWS9: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS10: Lilly Receives Positive CHMP Opinion for Emgality™ (galcanezumab) for the Prophylaxis of Migraine in Adults.NEWS11: Lilly migraine drug wins European panel thumbs-up.NEWS12: Lilly' Emgality Gets Positive CHMP Opinion For Prophylaxis Of Migraine In Adults.NEWS13: Lilly' Emgality Gets Positive CHMP Opinion For Prophylaxis Of Migraine In Adults.
2018-09-24: NEWS1: Cramer advises staying away from animal health play Elanc....NEWS2: Stay away from animal health play Elanco at these levels.NEWS3: Cramer advises staying away from animal health play Elanco at these levels.NEWS4: J&J&apos;s Esketamine Fails to Meet Endpoint in Phase III Study.NEWS5: Newly Public Elanco Seeks to Innovate With Offering Proceeds.NEWS6: Elanco Animal Health Incorporated Announces IPO Closing.NEWS7: Eli Lilly spin-off Elanco creating ‘disruptive’ opportunity in animal health: CEO.NEWS8: Lilly's Migraine Drug Emgality Wins Positive CHMP Opinion.NEWS9: Lilly's Migraine Drug Emgality Wins Positive CHMP Opinion.NEWS10: AstraZeneca's Diabetes Treatment Reduces Cardiovascular Risk.NEWS11: AstraZeneca's Diabetes Treatment Reduces Cardiovascular Risk.NEWS12: Elanco shares rally after successful IPO.NEWS13: Lilly&apos;s Migraine Drug Emgality Wins Positive CHMP Opinion.NEWS14: Elanco Announces Full Exercise of Additional Stock, Sets Date for Q3 Earnings.
2018-09-25: NEWS1: Elanco Animal Health IPO.NEWS2: Elanco Animal Health IPO.NEWS3: Elanco Animal Health IPO.NEWS4: A Brief Bird's Eye View of Fresh IPO Elanco Animal Health.NEWS5: Allergan’s Stock Price Performance in September.NEWS6: J&J's Esketamine Fails to Meet Endpoint in Phase III Study.NEWS7: J&J's Esketamine Fails to Meet Endpoint in Phase III Study.

Answer: Rise